We investigated relationship between galectin-3 (Gal-3) levels and T lymphocytes apoptosis and the activation rates in breast cancer during chemotherapy. We used plasma samples from 112 women classified into two groups: 70 women with breast cancer (BC) and submitted to neoadjuvant chemotherapy (3 cycles) and 42 healthy women used as controls. In the group of BC, blood samples were taken before each cycle of chemotherapy and Gal-3 levels was evaluated by ELISA sandwich. Flow cytometry was used to study T cells apoptosis and activation. Before treatment, median value of Gal-3 was 6.31 ng/ml (range 1.07 - 50.74) in BC and 0.84 ng/ml (range 0.00 - 4.82) in HC. Gal-3 levels were highest in plasmas from BC (p < 0.001). During the same period, proportions of apoptotic T lymphocytes were highest in BC compared to HC (p < 0.05). Similar results were observed about T cells activation. According to clinical symptoms, we observed, in the group of patients with a low or null response to chemotherapy, a positive correlation between gal-3 levels and tumor size (rho = 0.48; p = 0.010). In addition, we found a dynamic relationship between gal-3 levels, tumor size and T lymphocytes apoptosis rates during treatment depending to the cure efficiency. We suggest gal-3 plasma concentrations could be used as predictive biomarker for chemotherapy efficiency in breast cancer patients.
References
[1]
Gueye, S.M.K., Gueye, M., Coulbary, S.A., Diouf, A. and Moreau, J.C. (2016) Problématique de la prise en charge des cancers du sein au Sénégal: Une approche transversale. The Pan African Medical Journal, 25, Article No. 6.
https://doi.org/10.11604/pamj.2016.25.3.3785
[2]
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D., Pineros, M., Znaor, A. and Bray, F. (2019) Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. International Journal of Cancer, 144, 1941-1953. https://doi.org/10.1002/ijc.31937
[3]
Kadrofske, M.M., Openo, K.P. and Wang, J.L. (1998) The HumanLGALS3 (Galectin-3) Gene: Determination of the Gene Structure and Functional Characterization of the Promoter. Archives of Biochemistry and Biophysics, 349, 7-20.
https://doi.org/10.1006/abbi.1997.0447
[4]
Barondes, S.H., Cooper, D., Gitt, M.A. and Leffler, H. (1994) Galectins. Structure and Function of a Large Family of Animal Lectins. Journal of Biological Chemistry, 269, 20807-20810. https://doi.org/10.1016/S0021-9258(17)31891-4
[5]
Thijssen, V.L., Heusschen, R., Caers, J. and Griffioen, A.W. (2015) Galectin Expression in Cancer Diagnosis and Prognosis: A Systematic Review. Biochimica et Biophysica Acta (BBA): Reviews on Cancer, 1855, 235-247.
https://doi.org/10.1016/j.bbcan.2015.03.003
[6]
Moon, B.-K., Lee, Y.J., Battle, P., Jessup, J.M., Raz, A. and Kim, H.-R.C. (2001) Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis: Implication of Galectin-3 Function during Metastasis. The American Journal of Pathology, 159, 1055-1060.
https://doi.org/10.1016/S0002-9440(10)61780-4
[7]
Zhang, H., Liang, X., Duan, C., Liu, C. and Zhao, Z. (2014). Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer. PLoS ONE, 9, Article No. e103482.
https://doi.org/10.1371/journal.pone.0103482
[8]
Fukumori, T., Takenaka, Y., Yoshii, T., Kim, H.-R.C., Hogan, V., Inohara, H., Kagawa, S. and Raz, A. (2003) CD29 and CD7 Mediate Galectin-3-Induced Type II T-Cell Apoptosis. Cancer Research, 63, 8302-8311.
[9]
Nishi, Y., Sano, H., Kawashima, T., Okada, T., Kuroda, T., Kikkawa, K., Kawashima, S., Tanabe, M., Goto, T. and Matsuzawa, Y. (2007) Role of Galectin-3 in Human Pulmonary Fibrosis. Allergology International, 56, 57-65.
https://doi.org/10.2332/allergolint.O-06-449
[10]
Simovic Markovic, B., Nikolic, A., Gazdic, M., Bojic, S., Vucicevic, L., Kosic, M., Mitrovic, S., Milosavljevic, M., Besra, G. and Trajkovic, V. (2016) Galectin-3 Plays an Important Pro-Inflammatory Role in the Induction Phase of Acute Colitis by Promoting Activation of NLRP3 Inflammasome and Production of IL-1β in Macrophages. Journal of Crohn’s and Colitis, 10, 593-606.
https://doi.org/10.1093/ecco-jcc/jjw013
[11]
Tirkes, T., Hollar, M.A., Tann, M., Kohli, M.D., Akisik, F. and Sandrasegaran, K. (2013) Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria. RadioGraphics, 33, 1323-1341. https://doi.org/10.1148/rg.335125214
[12]
De luliis, F., Salerno, G., Taglieri, L., Lanza, R., Cardelli, P. and Scarpa, S. (2017) Circulating Neuregulin-1 and Galectin-3 Can Be Prognostic Markers in Breast Cancer. The International Journal of Biological Markers, 32, 333-336.
https://doi.org/10.5301/ijbm.5000262
[13]
Cardoso, A.C., Andrade, L.N., Bustos, S.O. and Chammas, R. (2016) Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments. Frontiers in Oncology, 6, Article No. 127. https://doi.org/10.3389/fonc.2016.00127
[14]
Rabinovich, G.A., Daly, G., Dreja, H., Tailor, H., Riera, C.M., Hirabayashi, J. and Chernajovsky, Y. (1999) Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen-Induced Arthritis via T Cell Apoptosis. Journal of Experimental Medicine, 190, 385-398. https://doi.org/10.1084/jem.190.3.385
[15]
Zubieta, M.R., Furman, D., Barrio, M., Bravo, A.I., Domenichini, E. and Mordoh J. (2006) Galectin-3 Expression Correlates with Apoptosis of Tumor-Associated Lymphocytes in Human Melanoma Biopsies. The American Journal of Pathology, 168, 1666-1675. https://doi.org/10.2353/ajpath.2006.050971
[16]
Stillman, B.N., Hsu, D.K., Pang, M., Brewer, C.F., Johnson, P., Liu, F.-T. and Baum, L.G. (2006) Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death. The Journal of Immunology, 176, 778-789.
https://doi.org/10.4049/jimmunol.176.2.778
[17]
Zhou, J., Wang, G., Chen, Y., Wang, H., Hua, Y. and Cai, Z. (2019) Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers. Journal of Cellular and Molecular Medicine, 23, 4854-4865. https://doi.org/10.1111/jcmm.14356
[18]
Curti, B.D., Koguchi, Y., Leidner, R.S., Rolig, A.S., Sturgill, E.R., Sun, Z., Wu, Y., Rajamanickam, V., Bernard, B. and Hilgart-Martiszus, I. (2021) Enhancing Clinical and Immunological Effects of Anti-PD-1 with Belapectin, a Galectin-3 Inhibitor. Journal for Immunotherapy of Cancer, 9, Article ID: e002371.
https://doi.org/10.1136/jitc-2021-002371
[19]
Delphi, L., Sepehri, H., Khorramizadeh, M.R. and Mansoori, F. (2015) Pectic-Oligoshaccharides from Apples Induce Apoptosis and Cell Cycle Arrest in MDA-MB-231 Cells, a Model of Human Breast Cancer. Asian Pacific Journal of Cancer Prevention, 16, 5265-5271. https://doi.org/10.7314/APJCP.2015.16.13.5265
